174 related articles for article (PubMed ID: 35833949)
21. FAP imaging in rare cancer entities-first clinical experience in a broad spectrum of malignancies.
Dendl K; Finck R; Giesel FL; Kratochwil C; Lindner T; Mier W; Cardinale J; Kesch C; Röhrich M; Rathke H; Gampp H; Ristau J; Adeberg S; Jäger D; Debus J; Haberkorn U; Koerber SA
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):721-731. PubMed ID: 34342669
[TBL] [Abstract][Full Text] [Related]
22. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.
Rahbar K; Ahmadzadehfar H; Kratochwil C; Haberkorn U; Schäfers M; Essler M; Baum RP; Kulkarni HR; Schmidt M; Drzezga A; Bartenstein P; Pfestroff A; Luster M; Lützen U; Marx M; Prasad V; Brenner W; Heinzel A; Mottaghy FM; Ruf J; Meyer PT; Heuschkel M; Eveslage M; Bögemann M; Fendler WP; Krause BJ
J Nucl Med; 2017 Jan; 58(1):85-90. PubMed ID: 27765862
[TBL] [Abstract][Full Text] [Related]
23. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
[TBL] [Abstract][Full Text] [Related]
24. Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot Study.
Ballal S; Yadav MP; Moon ES; Roesch F; Kumari S; Agarwal S; Tripathi M; Sahoo RK; Mangu BS; Tupalli A; Bal C
Thyroid; 2022 Jan; 32(1):65-77. PubMed ID: 34641705
[No Abstract] [Full Text] [Related]
25. Radiation Dosimetry for
Okamoto S; Thieme A; Allmann J; D'Alessandria C; Maurer T; Retz M; Tauber R; Heck MM; Wester HJ; Tamaki N; Fendler WP; Herrmann K; Pfob CH; Scheidhauer K; Schwaiger M; Ziegler S; Eiber M
J Nucl Med; 2017 Mar; 58(3):445-450. PubMed ID: 27660138
[TBL] [Abstract][Full Text] [Related]
26. Fibroblast Activation Protein Inhibitor Theranostics: The Case for Use in Sarcoma.
Hamacher R; Lanzafame H; Mavroeidi IA; Pabst KM; Kessler L; Cheung PF; Bauer S; Herrmann K; Schildhaus HU; Siveke JT; Fendler WP
PET Clin; 2023 Jul; 18(3):361-367. PubMed ID: 36997366
[TBL] [Abstract][Full Text] [Related]
27. Radiation Dosimetry and Biodistribution of
Meyer C; Dahlbom M; Lindner T; Vauclin S; Mona C; Slavik R; Czernin J; Haberkorn U; Calais J
J Nucl Med; 2020 Aug; 61(8):1171-1177. PubMed ID: 31836685
[TBL] [Abstract][Full Text] [Related]
28. Fibroblast activation protein targeted therapy using [
Liu Y; Watabe T; Kaneda-Nakashima K; Shirakami Y; Naka S; Ooe K; Toyoshima A; Nagata K; Haberkorn U; Kratochwil C; Shinohara A; Hatazawa J; Giesel F
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):871-880. PubMed ID: 34537893
[TBL] [Abstract][Full Text] [Related]
29.
Giesel FL; Kratochwil C; Lindner T; Marschalek MM; Loktev A; Lehnert W; Debus J; Jäger D; Flechsig P; Altmann A; Mier W; Haberkorn U
J Nucl Med; 2019 Mar; 60(3):386-392. PubMed ID: 30072500
[TBL] [Abstract][Full Text] [Related]
30. Feasibility of [
Unterrainer LM; Lindner S; Eismann L; Casuscelli J; Gildehaus FJ; Bui VN; Albert NL; Holzgreve A; Beyer L; Todica A; Brendel M; Cyran CC; Karl A; Stief CG; Ledderose ST; Unterrainer M; Bartenstein P; Wenter V; Kretschmer A
Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3571-3580. PubMed ID: 35325283
[TBL] [Abstract][Full Text] [Related]
31. Kidney Doses in
Mix M; Renaud T; Kind F; Nemer U; Yousetzadeh-Nowsha E; Moalosi TCG; Ormrane AM; Meyer PT; Ruf J
J Nucl Med; 2022 Feb; 63(2):253-258. PubMed ID: 34088773
[TBL] [Abstract][Full Text] [Related]
32. Response assessment using
Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
[TBL] [Abstract][Full Text] [Related]
33. Hematologic safety of
Groener D; Nguyen CT; Baumgarten J; Bockisch B; Davis K; Happel C; Mader N; Nguyen Ngoc C; Wichert J; Banek S; Mandel P; Chun FKH; Tselis N; Grünwald F; Sabet A
EJNMMI Res; 2021 Jul; 11(1):61. PubMed ID: 34216290
[TBL] [Abstract][Full Text] [Related]
34. Examining Absorbed Doses of Indigenously Developed
Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
[No Abstract] [Full Text] [Related]
35. [
Wu C; Zhang X; Zeng Y; Wu R; Ding L; Xia Y; Chen Z; Zhang X; Wang X
Eur J Nucl Med Mol Imaging; 2022 Dec; 50(1):194-204. PubMed ID: 36040490
[TBL] [Abstract][Full Text] [Related]
36. Renal Safety of [
Rosar F; Kochems N; Bartholomä M; Maus S; Stemler T; Linxweiler J; Khreish F; Ezziddin S
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205686
[No Abstract] [Full Text] [Related]
37. Design and Development of
Lindner T; Altmann A; Krämer S; Kleist C; Loktev A; Kratochwil C; Giesel F; Mier W; Marme F; Debus J; Haberkorn U
J Nucl Med; 2020 Oct; 61(10):1507-1513. PubMed ID: 32169911
[TBL] [Abstract][Full Text] [Related]
38. The value of tumor markers in men with metastatic prostate cancer undergoing [
Yordanova A; Linden P; Hauser S; Feldmann G; Brossart P; Fimmers R; Essler M; Holdenrieder S; Ahmadzadehfar H
Prostate; 2020 Jan; 80(1):17-27. PubMed ID: 31579967
[TBL] [Abstract][Full Text] [Related]
39. Posttherapeutic Critical Organ Dosimetry of Extensive 177Lu-PSMA Inhibitor Therapy With Metastatic Castration-Resistant Prostate Cancer: One Center Results.
Özkan A; Uçar B; Seymen H; Yildiz Yarar Y; Falay FO; Demirkol MO
Clin Nucl Med; 2020 Apr; 45(4):288-291. PubMed ID: 32049721
[TBL] [Abstract][Full Text] [Related]
40. Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: preliminary report in cancer patients.
Paganelli G; Zoboli S; Cremonesi M; Mäcke HR; Chinol M
Cancer Biother Radiopharm; 1999 Dec; 14(6):477-83. PubMed ID: 10850334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]